Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

NCT02819284 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

909

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndromes
Keratoconjunctivitis Sicca

Interventions

DRUG: KPI-121 0.25% Ophthalmic Suspension
DRUG: Vehicle of KPI-121 0.25% Ophthalmic Suspension

Sponsor

Kala Pharmaceuticals, Inc.